Eton Pharmaceuticals CCO Ipek Erdogan‑Trinkaus Receives Award

What Happened
Ipek Erdogan‑Trinkaus, Chief Commercial Officer of Eton Pharmaceuticals (ETON), received a grant of 80,000 performance‑vested restricted stock units (RSUs) on July 31, 2026. Each RSU represents the right to one share of common stock; the grant was reported as a derivative award with $0 cash paid. The award has no immediate cash value and will only convert to shares if the specified market condition is met.

Key Details

• Transaction date: 2026-07-31; Form 4 filed 2026-08-04 (filed on time).
• Grant type: Award/Grant (code A); 80,000 RSUs; acquisition reported at $0.00.
• Vesting condition: Award vests in full if the closing price of ETON equals or exceeds $72.36 for one trading day at any time before July 31, 2029. If that market condition is not met by that date, the award is forfeited in full.
• Each RSU converts to one share if vested. The reported 80,000 is the maximum and only number issuable under the award (no tiered target or range).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing note: the filer authorized a designated person to submit the Form 4 on their behalf.

Context
Performance‑vested RSUs are conditional awards that depend on meeting a stock‑price target rather than time‑based vesting. This grant is not a purchase or sale and does not indicate an immediate cash transaction; its future value depends entirely on ETON’s share price reaching the specified threshold before the three‑year deadline.